The article discusses the protection regime for clinical trial data internationally and outlines the applicable protection regime. In doing so, this article outlines how the data exclusivity regime can operate in parallel with the patent regime to add a layer of protection for the data. Such protection operates at a regulatory level to delay the entry of generic medications. Internationally, the data exclusivity regime, which has become an important contemporary tool in trade negotiations with poorer nations, works to detrimentally affect access to medicatio
The following is a law review interview with Professor Srividhya Ragavan on the issues in interpreta...
This article contributes to an ongoing academic and public policy dialogue over whether and on what ...
This article reexamines the sources of exclusivity for drugs, considers their limitations, and evalu...
The article discusses the protection regime for clinical trial data internationally and outlines the...
The article discusses the protection regime for clinical trial data internationally and outlines the...
This Article is set in the background of the consequences of the WTO’s prescriptions on patenting of...
This Article is set in the background of the consequences of the WTO’s prescriptions on patenting of...
This Article is set in the background of the consequences of the WTO’s prescriptions on patenting of...
This Article is set in the background of the consequences of the WTO’s prescriptions on patenting of...
Since the adoption of the WTO-TRIPS Agreement in 1994, there has been significant controversy over t...
Since the adoption of the WTO-TRIPS Agreement in 1994, there has been significant controversy over t...
Since the adoption of the WTO-TRIPS Agreement in 1994, there has been significant controversy over t...
69-88Data-exclusivity is one of the most controversial issues in the current discussion on pharmaceu...
The following is a law review interview with Professor Srividhya Ragavan on the issues in interpreta...
Data exclusivity is temporary exclusive user right on the clinical data that need to be submitted to...
The following is a law review interview with Professor Srividhya Ragavan on the issues in interpreta...
This article contributes to an ongoing academic and public policy dialogue over whether and on what ...
This article reexamines the sources of exclusivity for drugs, considers their limitations, and evalu...
The article discusses the protection regime for clinical trial data internationally and outlines the...
The article discusses the protection regime for clinical trial data internationally and outlines the...
This Article is set in the background of the consequences of the WTO’s prescriptions on patenting of...
This Article is set in the background of the consequences of the WTO’s prescriptions on patenting of...
This Article is set in the background of the consequences of the WTO’s prescriptions on patenting of...
This Article is set in the background of the consequences of the WTO’s prescriptions on patenting of...
Since the adoption of the WTO-TRIPS Agreement in 1994, there has been significant controversy over t...
Since the adoption of the WTO-TRIPS Agreement in 1994, there has been significant controversy over t...
Since the adoption of the WTO-TRIPS Agreement in 1994, there has been significant controversy over t...
69-88Data-exclusivity is one of the most controversial issues in the current discussion on pharmaceu...
The following is a law review interview with Professor Srividhya Ragavan on the issues in interpreta...
Data exclusivity is temporary exclusive user right on the clinical data that need to be submitted to...
The following is a law review interview with Professor Srividhya Ragavan on the issues in interpreta...
This article contributes to an ongoing academic and public policy dialogue over whether and on what ...
This article reexamines the sources of exclusivity for drugs, considers their limitations, and evalu...